Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia: Update Bulletin [July 2014]

Product Code:
596200286
Release Date:
July 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Chronic Lymphocytic Leukaemia: GSK/Genmab’s Arzerra; Roche’s Gazyvaro, ABT-199; Pharmacyclics/Janssen’s Imbruvica

Highlights from this event update bulletin

  • EU extended approval of Arzerra to the first line will increase its usage
  • Gazyvaro will successfully compete with MabThera in the EU
  • Oncologists will be keen to use Gazyvaro in combination with other chemotherapy regimens
  • Biosimilar rituximab will struggle to compete with Gazyvaro
  • Early data show high response rates for ABT-199
  • ABT-199 will have a likely role in combination therapy in the relapsed/refractory setting
  • ABT-199 lags behind the BTK inhibitors in the race to market and for clinician acceptance
  • TLS associated with ABT-199 can be safely managed
  • RESONATE data will strengthen Imbruvica’s lead in the relapsed/refractory setting
  • RESONATE data confirm that Imbruvica is relatively well tolerated
  • Imbruvica may move into first-line use for hard-to-treat patients

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved